Takeda Completes CEO Transition with Julie Kim at Helm
Event summary
- Julie Kim officially appointed as Takeda’s Representative Director, President and CEO on June 24, 2026.
- Former CEO Christophe Weber retired after 12 years of service.
- Three new external directors elected to the Board: Bruce Broussard, Koichiro Kimura, and Dr. Paul Stoffels.
- Takeda plans three major drug launches in the next 12 months and has five additional late-stage assets in development.
The big picture
Takeda’s CEO transition marks the end of an era under Christophe Weber, who expanded the company’s global scale and innovative pipeline. The appointment of Julie Kim, with her extensive healthcare experience, signals a focus on long-term growth and patient impact. The addition of three new external directors with diverse expertise in healthcare, geopolitical risk, and R&D innovation underscores Takeda’s commitment to strengthening its governance and strategic direction.
What we're watching
- Pipeline Execution
- Whether Takeda can deliver on its three major drug launches and five late-stage assets within the next year.
- Board Dynamics
- How the new external directors will influence strategic decisions and corporate governance.
- Leadership Impact
- The pace at which Julie Kim can drive profitable growth and maintain Takeda’s global reputation.
Related topics